How and Why to Treat Plexiform Neurofibromas

Educational only, not medical advice. If you or your child has neurofibromatosis type 1 (NF1) or a plexiform neurofibroma (PN), decisions about treatment should be made with an experienced care teamideally an NF clinic with multiple specialists. (Because “Dr. Google” is not board-certified, and also because Dr. Google never returns your calls.)

What plexiform neurofibromas are (and why they can be such a big deal)

Plexiform neurofibromas are benign (noncancerous) tumors that grow along nerves. They’re strongly associated with NF1, a genetic condition that can affect the skin, nervous system, and other organs. Many plexiform neurofibromas start early in life and may grow over time. Some are visible and create swelling or asymmetry; others sit deeper in the body and only show themselves by the trouble they cause.

If you’ve ever heard a clinician describe a plexiform neurofibroma as feeling like a “bag of worms,” that’s not an insultit’s a classic physical-exam clue. PNs can weave through tissues and wrap around blood vessels, nerves, and organs in a way that makes them hard to remove completely.

Common symptoms and complications

• Pain (often nerve-related, sometimes constant, sometimes flaring)
• Functional problems (weakness, numbness, limited range of motion, trouble walking or using an arm/hand)
• Compression issues (pressure on the airway, bowel/bladder, spine, or other vital structures depending on location)
• Cosmetic and body-image impact (visible growths can carry a heavy social and emotional cost)
• Risk of cancerous change (uncommon, but importantPNs can rarely transform into malignant peripheral nerve sheath tumor, or MPNST)

Why treat plexiform neurofibromas?

Not every plexiform neurofibroma needs treatment right away. Many people live with stable tumors for years with careful monitoring. Treatment becomes a conversation when the tumor is causing (or is likely to cause) meaningful harm.

The “why” usually comes down to quality of life and protecting function

• Relieve symptoms: reduce pain, improve movement, protect breathing/vision/swallowing, or make daily life less exhausting.
• Prevent or limit damage: stop a tumor from compressing nerves, the spinal cord, or organs.
• Reduce tumor size when surgery isn’t feasible: modern targeted medicines can shrink some tumors and may make future procedures safer.
• Address psychosocial impact: appearance-related distress, stigma, anxiety, and depression deserve real attentionnot a shrug and a “be strong.”

One of the most important mindset shifts in PN care is this: treatment is not just about what a scan shows. It’s also about what the tumor is doing to a person’s lifesleep, school, work, mobility, confidence, relationships, and the ability to do normal human things like sit comfortably in a car or wear a backpack without wincing.

How clinicians decide: monitor vs treat

Think of PN management as a structured “risk vs burden” calculation. Doctors look at tumor size and location, growth rate, symptoms, and the risks of each intervention. There’s no single universal pathway, which is why NF specialty care matters.

Monitoring (watchful waiting) is common when:

• The PN is stable or slow-growing
• Symptoms are mild and manageable
• The tumor is not threatening vital structures
• The risks of treatment outweigh the potential benefits right now

Treatment is more likely when:

• Pain becomes persistent or increasingly difficult to control
• Function is affected (weakness, numbness, impaired gait, reduced dexterity)
• Organ/airway/spinal cord compression is suspected or documented
• Disfigurement is severe and impacting psychosocial health
• There are red flags suggesting possible malignant change (more on that below)

Real-life example: A PN in the neck may be considered “inoperable” if it encases blood vessels or threads through nerves that control swallowing and voice. In that case, a team might prioritize medicine to shrink the tumor or slow growth, rather than risk a surgery that could trade one problem for several new ones.

The work-up: what “good evaluation” looks like

Because plexiform neurofibromas can hide deep and grow in complex shapes, evaluation usually involves a combination of clinical exams, symptom tracking, and imaging.

Imaging and surveillance

• MRI is the main imaging tool for defining size, location, and effect on nearby structures. Specialized centers often use volumetric measurements for a more accurate sense of change over time.
• CT may be used in select situations (often when MRI isn’t feasible), but MRI is preferred for soft tissues and nerves.
• PET scans are not typically used to diagnose PN, but they may help when clinicians are concerned about malignant transformation, since more aggressive tumors can show higher metabolic activity.

The underrated tool: the symptom “timeline”

Scans are essential, but so is your lived experience. A simple timelinepain level, sleep disruption, new weakness, new tingling, changes in a visible mass, headaches, breathing issueshelps the team connect symptoms to tumor behavior. It also helps distinguish “this hurts because it hurts” from “this hurts because something changed.” That difference matters.

Treatment option 1: Surgery (helpful, but not always possible)

Surgery remains an important option, especially when a PN is localized enough to remove safely or when debulking (partial removal) can relieve pressure on structures. The challenge is that plexiform neurofibromas often grow into and around nerves and tissues, making complete resection difficult without causing injury.

When surgery tends to make sense

• A discrete part of the tumor is causing a specific problem (for example, compressing a nerve and triggering severe pain)
• The tumor’s anatomy suggests it can be removed with acceptable risk
• There is concern about atypical features that warrant biopsy or removal of a suspicious segment

Common realities (the part nobody loves to say out loud)

• Complete removal may not be possible
• Regrowth can occur
• Risks include bleeding, nerve damage, and slow healingespecially when tumors are highly vascular or intertwined with vital structures

Treatment option 2: Targeted medicines (MEK inhibitors changed the game)

For years, surgery was the only meaningful treatment for many symptomatic, inoperable plexiform neurofibromas. That changed with targeted therapyespecially drugs called MEK inhibitors, which block part of the overactive signaling pathway involved in NF1 tumor growth.

Selumetinib (KOSELUGO)

Selumetinib is a MEK inhibitor with U.S. FDA approvals for NF1-related plexiform neurofibromas in specific groups, including pediatric patients (down to age 1 year for symptomatic, inoperable PN) and adults with symptomatic, inoperable PN. In plain English: it’s a legitimate, regulated optionnot a supplement, not a “protocol,” not something sold by a stranger who calls you “dear.”

Mirdametinib (GOMEKLI)

Mirdametinib is another MEK inhibitor FDA-approved for adults and children (age 2 and older) with NF1 who have symptomatic plexiform neurofibromas not amenable to complete resection. Response in studies is often defined as at least a 20% reduction in tumor volume on volumetric MRIan important benchmark because PNs can be irregular, and “diameter” doesn’t tell the whole story.

What patients can realistically expect

• Potential tumor shrinkage (sometimes meaningful, sometimes modesteither can matter depending on location)
• Symptom improvement (pain reduction, better function, less compression-related trouble)
• Not a cure (these medicines manage the disease; they don’t erase NF1)
• Ongoing monitoring (because benefits and side effects both require supervision)

Side effects and monitoring (important, not optional)

MEK inhibitors can cause side effects that range from annoying to serious. The most common issues include rash and gastrointestinal symptoms (like diarrhea and nausea), fatigue, and lab abnormalities such as elevated creatine phosphokinase (CPK). Some MEK inhibitors also carry risks of heart (left ventricular) dysfunction and eye toxicity, which is why clinicians monitor symptoms, labs, and sometimes heart function and ophthalmologic exams depending on the medication and patient factors.

Practical tip: If you start a MEK inhibitor, treat follow-up appointments like they’re part of the prescriptionbecause they are. Dose holds, reductions, or discontinuation may be needed if side effects become significant.

Treatment option 3: Supportive care (because pain and function matter)

Even when a PN is being monitoredor actively treated with surgery or medicinesupportive care is not “extra.” It’s the quality-of-life backbone.

Pain management

PN pain can be neuropathic (nerve-related), mechanical (pressure and stretching), inflammatory, or a mix. Treatment may include nerve-pain medications, physical strategies, and behavioral approaches that reduce suffering and improve function. Many NF programs also emphasize assessing pain in a structured way, because chronic pain is a full-time job that doesn’t come with benefits.

Physical and occupational therapy

PT and OT can help maintain strength, balance, endurance, and daily skillsespecially when a PN affects mobility or fine motor function. This is particularly relevant in children, where function and development are moving targets (in the good way) and early support can make a lasting difference.

Mental health and social support

Living with a visible tumor or chronic pain can produce anxiety, depression, social withdrawal, and body-image distress. Counseling, peer support, and accommodations at school or work can be the difference between “surviving” and actually living. If your care plan never mentions mental health, consider that a gap worth fixing.

Red flags: when “we’ll just watch it” should become “call the team today”

Most plexiform neurofibromas do not become cancerous, but vigilance matters because malignant peripheral nerve sheath tumors (MPNSTs) can be aggressive. Contact your clinician promptly if you notice:

• Rapid growth of a known tumor
• New, persistent, or worsening pain (especially deep pain that’s different from baseline)
• Hardening of a previously soft area
• New weakness, numbness, or loss of function
• Systemic symptoms such as unexplained fevers or significant weight loss (less common, but important)

These symptoms don’t automatically mean cancer, but they do mean the situation deserves prompt evaluation.

Questions to ask your NF care team

1. Is this PN considered operable, partially operable, or inoperableand why?
2. What outcomes are we targeting: pain relief, function, reduced compression, appearance, or all of the above?
3. How will we measure changesymptoms, MRI volume, function tests, or a combination?
4. Am I (or is my child) a candidate for a MEK inhibitor? Which one, and why?
5. What side effects should we watch for, and what monitoring schedule will we follow?
6. What would make us stop, pause, or change treatment?
7. Are there clinical trials that match this tumor’s location and symptom profile?
8. What supportive therapies (PT/OT, pain psychology, school/work accommodations) should we start now?

Bottom line: treating PNs is about the person, not just the tumor

Plexiform neurofibromas can be quiet passengers or loud disruptors. The goal of treatment is to reduce harmpain, disability, organ compromise, and emotional burdenwhile avoiding unnecessary risk. The growing list of evidence-based options (from surgery to MEK inhibitors to supportive therapies) means more individualized plans and fewer “sorry, there’s nothing we can do” moments.

If you take one thing from this article, let it be this: NF1-associated PNs are complex enough that they deserve specialized, multidisciplinary care. When the right team is involved, the plan becomes clearer, the monitoring becomes smarter, and the future becomes less of a question mark and more of a schedule.

Experiences With Treating Plexiform Neurofibromas (Real-World, Human-Level)

When people talk about plexiform neurofibromas outside of a clinic, the conversation is rarely about “volumetric response criteria.” It’s about the daily stuff: sleep, clothes that fit, whether a backpack strap triggers a pain flare, and how long it takes to explain NF1 to someone who thinks it’s contagious (it’s not).

The first experience many families share is uncertainty. A PN may show up early, sometimes before a child can describe symptoms clearly. Parents often describe a strange mix of “we can see it” and “we can’t predict it.” Some tumors grow slowly for years. Others seem to hit a growth spurt, especially in childhood. That unpredictability can make every new photo, every new complaint of soreness, and every checkup feel like a high-stakes pop quiz nobody studied for.

Then comes the decision fork: watch, cut, or medicate. Watchful waiting can sound passive, but in real life it’s active monitoringtracking symptoms, taking periodic imaging seriously, and learning what “normal for us” means. Some people find it reassuring: “We’re not rushing into risks.” Others find it emotionally exhausting: “We’re waiting for something to happen.” Both reactions are valid. If you’re in the second group, a structured plan (what to watch for, when to call, when imaging happens) can turn “waiting” into “working the plan.”

Surgery experiences tend to be… nuanced. When surgery is possible, it can be a reliefespecially if a specific part of the tumor is causing pain or compressing something important. But many patients describe surgery as an ongoing relationship rather than a one-time event. Debulking can help and still leave tumor behind. Recovery can involve physical therapy, temporary loss of function, or scar management. And some people carry a very real fear: “What if we trade the tumor’s symptoms for nerve damage?” A good surgical team will talk about that openly, including the realistic best-case and worst-case scenarios, not just the sunny brochure version.

MEK inhibitor experiences often sound like: ‘Finally, something happened.’ For families who’ve been told for years that a tumor is inoperable, starting a targeted therapy can feel like switching on a light in a room that’s been dim for too long. People commonly describe early hopes (“Maybe the swelling will go down”) alongside practical worries (“What will the side effects be?”). Some patients report improved pain or function even before there’s dramatic shrinkage on imagingbecause a small decrease in volume, in the right spot, can matter a lot. At the same time, side effects can be real: skin rashes that change skincare routines, stomach issues that turn meal planning into strategy, and fatigue that requires new pacing habits. The experience becomes a balancing act: tracking benefits, reporting issues early, and making dose adjustments without feeling like you “failed” the medication. (You didn’t. That’s just medicine doing what medicine doesrequiring customization.)

One of the most consistent themes is the value of support. Patients and parents often mention that the best NF clinics don’t just prescribethey coordinate. They connect the dots between neurology, oncology, surgery, rehab, pain management, and mental health. And outside the clinic, community matters. Support groups (online or in person) can normalize the weird stuff: explaining café-au-lait spots, dealing with stares, preparing school accommodation letters, or finding language for a pain flare that doesn’t sound like “I’m fine, I guess.”

Finally, there’s the identity piece. Many people living with NF1 and PNs describe a long-term shift from “I want this gone” to “I want my life bigger than this.” Treatment can help shrink a tumor, reduce pain, and protect functionbut confidence, comfort in public, and long-term resilience often grow through counseling, advocacy, supportive relationships, and learning that you’re allowed to take up space exactly as you are. And yes: humor belongs here too. Sometimes the ability to laugh at the absurdity (“My tumor has better attendance than I do”) is a real coping toolnot denial, just survival with a grin.